If mechanistic theories that SGLT-2 inhibitors slow CKD progression by lowering intraglomerular pressure are correct [13], renal benefits may be smaller in the absence of albuminuria (a marker of intraglomerular hypertension). The gene discussed is SLC5A2; the disease is Hypertension.